Legacy Capital Wealth Partners LLC Invests $223,000 in Danaher Co. (NYSE:DHR)

Legacy Capital Wealth Partners LLC acquired a new stake in shares of Danaher Co. (NYSE:DHR) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 893 shares of the conglomerate’s stock, valued at approximately $223,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. Norges Bank purchased a new position in shares of Danaher in the 4th quarter worth approximately $1,752,382,000. Vanguard Group Inc. increased its position in shares of Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after purchasing an additional 4,163,657 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after purchasing an additional 2,998,161 shares during the last quarter. Swedbank AB acquired a new stake in shares of Danaher in the 1st quarter worth $676,545,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in Danaher by 214.4% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock worth $711,051,000 after buying an additional 2,096,038 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research analyst reports. Royal Bank of Canada increased their price target on Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI lowered their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Stifel Nicolaus raised their price target on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Finally, Wells Fargo & Company started coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $278.94.

Danaher Stock Performance

Shares of DHR stock opened at $264.49 on Thursday. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The stock has a market cap of $195.90 billion, a PE ratio of 44.83, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The business has a 50-day simple moving average of $260.72 and a 200-day simple moving average of $255.55.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the firm posted $2.05 EPS. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. On average, equities analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.